A Phase 2 interventional study of BNT111 and Cemiplimab in Melanoma Stage III, Melanoma Stage IV and Unresectable Melanoma, sponsored by BioNTech SE. Completed at 49 sites in 7 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-01-08.
Sponsored by BioNTech SE · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies testing cemiplimab in Melanoma — 6 open to participants now, 9 under way, 1 of them phase 3. cemiplimab · Melanoma.
Among the 11 studies testing cemiplimab in Melanoma, this one is the 3rd largest by enrollment, is the only one that started in 2021, is one of 8 in phase 2, and was the 3rd registered.
3,373 studies on the registry are indexed under Melanoma; 580 are open to participants now.
Browse Melanoma studies →6 of the 11 studies testing cemiplimab in Melanoma are open now, in 3 countries. Recruiting first, the newest first:
Grupo Español Multidisciplinar de Melanoma · Sites in Spain
Ages 18+
Regeneron Pharmaceuticals · Sites in United States
Ages 18+
Memorial Sloan Kettering Cancer Center · Sites in United States
Ages 18+
Regeneron Pharmaceuticals · Sites in United States, Canada
Ages 18+
University of California, Irvine · Sites in United States
By country, each count listing its studies:
cemiplimab: first FDA approval 2018 (LIBTAYO), first EMA approval 2019. What it is approved for, and how studies give it, is on its page →
Of the 468 Melanoma studies recruiting now, 381 (81%) set no upper age limit and 49 (10%) stop at 75 or younger; 47 take children under 18; 29 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 9 · Phase 3 1
First in 2017; this study’s year is marked. 1 started in 2021.
This study's enrollment of 184 is above the median of 40 across 2,650 interventional studies indexed under Melanoma.
Median enrollment 87 across the 11 interventional studies. Of the 2 that completed or were terminated, 1 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
7 of 11 have an industry lead sponsor. The 7 most frequent:
BioNTech SE is the lead sponsor of 76 studies on the registry; 25 are open to participants now.
Of its 33 completed or terminated interventional studies of FDA-regulated products, 26 (79%) have results posted.
BioNTech SE has 9 studies filed under Melanoma — fewer than ten, so there is no comparison to draw.
2 of the studies testing cemiplimab in Melanoma that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06246916Phase 3Regeneron PharmaceuticalsA Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head) | 2027-03-22 |
| NCT06594991Memorial Sloan Kettering Cancer CenterA Study of Fianlimab, Cemiplimab, and Ipilimumab in People With Melanoma | 2027-09 |
Add all 2 to your calendar (.ics) → With an account.
Among the 11 studies testing cemiplimab in Melanoma, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is an open-label, randomized, multi-site, Phase II, interventional trial designed to evaluate the efficacy, tolerability, and safety of BNT111 + cemiplimab in anti-programmed death protein 1 (PD-1)/anti-programmed death ligand 1 (PD-L1)-refractory/relapsed patients with unresectable Stage III or IV melanoma. The contributions of BNT111 and cemiplimab will be delineated in single agent calibrator arms. Patients will be randomized in a 2:1:1 ratio to Arm 1 (BNT111 + cemiplimab) and calibrator Arm 2 (BNT111 monotherapy), and Arm 3 (cemiplimab monotherapy). Patients in single agent calibrator arms (Arms 2 and 3), who experience centrally verified disease progression under single agent treatment, may be offered addition of the other compound to the ongoing treatment after re-consent.
Inclusion Criteria:
Patients must have confirmed disease progression on/after an approved /PD-L1 regimen for melanoma as defined by RECIST v1.1.
Patients with BRAF V600-positive tumor(s) should have received prior treatment with a BRAF inhibitor (alone or in combination with a mitogen-activated protein kinase kinase [MEK] inhibitor).
Patients must provide the following samples:
Exclusion Criteria:
Patients must have no ongoing or recent evidence (within the last 5 years) of significant disease that required treatment with systemic treatments which may pose a risk for irAEs.
Patients must have no uncontrolled infection with (HIV), or infection; or diagnosis of immunodeficiency that is related to, or results in chronic infection. Mild cancer-related immunodeficiency (such as immunodeficiency treated with gamma globulin and without chronic or recurrent infection) is allowed.
Current use or use within 3 months prior to trial enrollment of systemic immune suppression including:
Current evidence of new or growing brain or spinal metastases during screening. Patients with are excluded. Patients with known brain or spinal metastases may be eligible if they:
History or current evidence of significant cardiovascular disease including, but not limited to:
Inclusion criteria for entering add-on therapy
Patients must have confirmed disease progression on monotherapy in Arm 2 or 3 of the trial.
Exclusion criteria for entering add-on therapy
Systemic immune suppression:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
PD-1, PD-L1 and checkpoint inhibitors
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Reproductive potential
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CD4 count
The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CTCAE grade
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Leptomeningeal disease
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biological: BNT111 · Biological: Cemiplimab
Biological: BNT111
Biological: Cemiplimab
IV injection
IV infusion
Arm 1: Objective Response Rate (ORR)
ORR was defined as the percentage of participants in whom a complete response (CR) or partial response (PR) according to response evaluation criteria in solid tumors version 1.1 (RECIST v1.1) was observed as best overall response by blinded independent central review (BICR). Per RECIST 1.1 criteria, CR defined as the disappearance of all target lesions and PR was defined as the \>=30% decrease in the sum of the longest diameter of target lesions.
Time frame: Up to 24 months
Arms 2 & 3: Objective Response Rate (ORR)
ORR is defined as the percentage of participants in whom a CR or PR according to RECIST v1.1 observed as best overall response by BICR. Data for this outcome measure will be reported at the time of final results posting.
Time frame: Up to 24 Months
Duration of Response (DOR) As Assessed by Blinded Independent Central Review (BICR)
DOR is defined as the time from first objective response (CR or PR) to first occurrence of objective tumor progression (progressive disease, PD) by BICR or death from any cause (whichever occurs first). Data for this outcome measure will be reported at the time of final results posting.
Time frame: Up to 24 Months
Disease Control Rate (DCR) As Assessed by BICR
DCR is defined as the percentage of participants in whom a CR, PR or stable disease (SD; assessed at least 6 weeks after first dose) is observed as best overall response by BICR. Data for this outcome measure will be reported at the time of final results posting.
Time frame: Up to 24 months
Time to Response (TTR) As Assessed by BICR
TTR is defined as the time from randomization to the first objective tumor response (CR or PR) by BICR. Data for this outcome measure will be reported at the time of final results posting.
Time frame: Up to 24 months
Progression-Free Survival (PFS) As Assessed by BICR
PFS is defined as the time from randomization to first objective tumor progression (PD) by BICR or death from any cause (whichever occurs first). Data for this outcome measure will be reported at the time of final results posting.
Time frame: Up to 24 Months
Objective Response Rate (ORR) As Assessed by the Investigator
ORR is defined as the percentage of participants in whom a CR or PR according to RECIST v1.1 observed as best overall response by investigator. Data for this outcome measure will be reported at the time of final results posting.
Time frame: Up to 24 months
Duration of Response (DOR) As Assessed by the Investigator
DOR is defined as the time from first objective response (CR or PR) to first occurrence of objective tumor progression (progressive disease, PD) by BICR or death from any cause (whichever occurs first). Data for this outcome measure will be reported at the time of final results posting.
Time frame: Up to 24 Months
Disease Control Rate (DCR) As Assessed by the Investigator
DCR defined as the percentage of participants in whom a CR, PR or stable disease (SD; assessed at least 6 weeks after first dose) is observed as best overall response by investigator. Data for this outcome measure will be reported at the time of final results posting.
Time frame: Up to 24 months
Time to Response (TTR) As Assessed by the Investigator
TTR is defined as the time from randomization to the first objective tumor response (CR or PR) as assessed by investigator. Data for this outcome measure will be reported at the time of final results posting.
Time frame: Up to 24 months
Progression-Free Survival (PFS) As Assessed by the Investigator
PFS is defined as the time from randomization to first objective tumor progression (PD) by investigator or death from any cause (whichever occurs first). Data for this outcome measure will be reported at the time of final results posting.
Time frame: Up to 24 Months
Arm 1: Overall Survival (OS)
OS is defined as the time from randomization to death from any cause. Data for this outcome measure will be reported at the time of final results posting.
Time frame: Up to 48 months
Number of Participants With Treatment-Emergent Adverse Events (TEAEs)
A treatment-emergent adverse event (TEAE) is defined as any AE with an onset date on or after the first administration of trial treatment (if the AE was absent before the first administration of trial treatment) or worsened after the first administration of trial treatment (if the AE was present before the first administration of trial treatment). Data for this outcome measure will be reported at the time of final results posting.
Time frame: Up to 27 months
Number of Participants With Immune-Related Adverse Events (irAE)
AEs related to the use of immune checkpoint inhibitor (ICI) therapy are defined as immune-related (IR) AEs (irAEs). Data for this outcome measure will be reported at the time of final results posting.
Time frame: Up to 27 months
Number of Participants Reporting Dose Reduction and Discontinuation Due to TEAE
Participants with dose reduction and discontinuation due to TEAE will be reported. Data for this outcome measure will be reported at the time of final results posting.
Time frame: Up to 27 months
Change From Baseline in Laboratory Parameters Values: Hematology: Basophils
Blood samples will be collected for the assessment of hematology parameters. Data for this outcome measure will be reported at the time of final results posting.
Time frame: From Baseline up to 25 months
Change From Baseline in Laboratory Parameters Values: Hematology: Eosinophils
Blood samples will be collected for the assessment of hematology parameters. Data for this outcome measure will be reported at the time of final results posting.
Time frame: From Baseline up to 25 months
Change From Baseline in Laboratory Parameters Values: Hematocrit
Blood samples will be collected for the assessment of hematology parameters. Data for this outcome measure will be reported at the time of final results posting.
Time frame: From Baseline up to 25 months
Change From Baseline in Laboratory Parameters Values: Hemoglobin
Blood samples will be collected for the assessment of hematology parameters. Data for this outcome measure will be reported at the time of final results posting.
Time frame: From Baseline up to 25 months
Change From Baseline in Laboratory Parameters Values: Hematology: Lymphocytes
Blood samples will be collected for the assessment of hematology parameters. Data for this outcome measure will be reported at the time of final results posting.
Time frame: From Baseline up to 25 months
Change From Baseline in Laboratory Parameters Values: Clinical Chemistry: Albumin
Blood samples will be collected for the assessment of clinical chemistry parameters. Data for this outcome measure will be reported at the time of final results posting.
Time frame: From Baseline up to 25 months
Change From Baseline in Laboratory Parameters Values: Clinical Chemistry: Alkaline Phosphatase
Blood samples will be collected for the assessment of clinical chemistry parameters. Data for this outcome measure will be reported at the time of final results posting.
Time frame: From Baseline up to 25 months
Change From Baseline in Laboratory Parameters Values: Clinical Chemistry: Alanine Aminotransferase
Blood samples will be collected for the assessment of clinical chemistry parameters. Data for this outcome measure will be reported at the time of final results posting.
Time frame: From Baseline up to 25 months
Change From Baseline in Laboratory Parameters Values: Clinical Chemistry: Amylase
Blood samples will be collected for the assessment of clinical chemistry parameters. Data for this outcome measure will be reported at the time of final results posting.
Time frame: From Baseline up to 25 months
Change From Baseline in Laboratory Parameters Values: Clinical Chemistry: Aspartate Aminotransferase
Blood samples will be collected for the assessment of clinical chemistry parameters. Data for this outcome measure will be reported at the time of final results posting.
Time frame: From Baseline up to 25 months
Change From Baseline in Laboratory Parameters Values: Clinical Chemistry: Bilirubin
Blood samples will be collected for the assessment of clinical chemistry parameters. Data for this outcome measure will be reported at the time of final results posting.
Time frame: From Baseline up to 25 months
Change From Baseline in Laboratory Parameters Values: Clinical Chemistry: Creatine Kinase
Blood samples will be collected for the assessment of clinical chemistry parameters. Data for this outcome measure will be reported at the time of final results posting.
Time frame: From Baseline up to 25 months
Change From Baseline in Laboratory Parameters Values: Clinical Chemistry: Creatinine
Blood samples will be collected for the assessment of clinical chemistry parameters. Data for this outcome measure will be reported at the time of final results posting.
Time frame: From Baseline up to 25 months
Change From Baseline in Laboratory Parameters Values: Clinical Chemistry: C-Reactive Protein
Blood samples will be collected for the assessment of clinical chemistry parameters. Data for this outcome measure will be reported at the time of final results posting.
Time frame: From Baseline up to 25 months
Change From Baseline in Laboratory Parameters Values: Coagulation Factors: Activated Partial Thromboplastin Time
Blood samples will be collected for the assessment of coagulation factors. Data for this outcome measure will be reported at the time of final results posting.
Time frame: From Baseline up to 25 months
Change From Baseline in Laboratory Parameters Values: Coagulation Factors: Prothrombin Time
Blood samples will be collected for the assessment of coagulation factors. Data for this outcome measure will be reported at the time of final results posting.
Time frame: From Baseline up to 25 months
Change From Baseline in Laboratory Parameters Values: Endocrine Tests: Thyroxine
Blood samples will be collected for the assessment of endocrine tests. Data for this outcome measure will be reported at the time of final results posting.
Time frame: From Baseline up to 25 months
Change From Baseline in Laboratory Parameters Values: Urinalysis: pH
Urine samples will be collected for the assessment of pH. Data for this outcome measure will be reported at the time of final results posting.
Time frame: From Baseline up to 25 months
Number of Participants With Clinically Significant Abnormalities in Laboratory Parameters
Participants with clinically significant abnormalities in laboratory parameters will be reported. Data for this outcome measure will be reported at the time of final results posting.
Time frame: Up to 25 months
Change From Baseline in Vital Signs Parameters: Systolic Blood Pressure
Systolic blood pressure (in mmHg) will be assessed. Data for this outcome measure will be reported at the time of final results posting.
Time frame: From Baseline up to 25 months
Change From Baseline in Vital Signs Parameters: Diastolic Blood Pressure
Diastolic blood pressure (in mmHg) will be assessed. Data for this outcome measure will be reported at the time of final results posting.
Time frame: From Baseline up to 25 months
Change From Baseline in Vital Signs Parameters: Heart Rate
Heart rate (in beats per minute) will be assessed. Data for this outcome measure will be reported at the time of final results posting.
Time frame: From Baseline up to 25 months
Change From Baseline in Vital Signs Parameters: Respiratory Rate
Respiratory Rate (in breaths per minute) will be assessed. Data for this outcome measure will be reported at the time of final results posting.
Time frame: From Baseline up to 25 months
Change From Baseline in Vital Signs Parameters: Body Temperature
Body Temperature (in degree Celsius) will be assessed. Data for this outcome measure will be reported at the time of final results posting.
Time frame: From Baseline up to 25 months
Number of Participants With Clinically Significant Abnormalities in Vital Signs
Participants with clinically significant abnormalities in vital sign parameters will be reported. Data for this outcome measure will be reported at the time of final results posting.
Time frame: Up to 25 months
Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 Items (EORTC QLQ-C30) Global Health Status Total Score
Mean change from baseline in the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 Items (EORTC QLQ-C30) Global Health Status Score will be reported. Each item, except Global Health Status, is answered on a four-point scale (1-4): 1-not at all, 2-a little, 3-quite a bit, 4-very much. Response to Global Health Status is measured on a 1 to 7 scale. "1" being very poor and "7" being excellent. Positive changes indicated better health status or functioning, and negative changes indicated worsening of health status or functioning. Scale scores range from 0 to 100. Raw data was linearly transformed to be in a range from 0-100 where a higher score represents good health status, while lower scores indicate poor health status. Data for this outcome measure will be reported at the time of final results posting.
Time frame: From Baseline up to 25 months
Change From Baseline in EORTC QLQ-C30 Functional Scales Score
The EORTC QLQ-C30 questionnaire incorporates nine multi-item scales: 5 functional scales (physical, cognitive, role, emotional, and social); 3 symptom scales (pain, fatigue, and appetite loss) and a Global Health Status/QoL scale. EORTC QLQ-C30 Physical Functioning Score is a questionnaire to assess quality of life of cancer patients. It is composed of 30 items, multi-item measure (28 items) and 2 single-item measures. For the multiple item measure, 4-point scale is used and the score for each item range from "1 = not at all" to "4 = very much". Higher scores indicate worsening of symptoms. Data for this outcome measure will be reported at the time of final results posting.
Time frame: From Baseline up to 25 months
Changes From Baseline in EORTC QLQ-C30 Symptoms Scales Score
The EORTC QLQ-C30 questionnaire incorporates nine multi-item scales: 5 functional scales (physical, cognitive, role, emotional, and social); 3 symptom scales (pain, fatigue, and appetite loss) and a Global Health Status/QoL scale. Each item, except Global Health Status, is answered on a four-point scale (1-4): 1-not at all, 2-a little, 3-quite a bit, 4-very much. Each scale (symptom scale \[pain, fatigue, and appetite loss\] and Global Health Status/Quality of Life \[QoL\] scale) was linearly transformed to be in range from 0-100 where a higher score represents good health status, while lower scores indicate poor health status. Data for this outcome measure will be reported at the time of final results posting.
Time frame: From Baseline up to 25 months
Time to First Clinically Meaningful Deterioration in Global Health Status Score as Measured by EORTC QLQ-C30
Time to first clinically meaningful deterioration in global health status score as measured by EORTC QLQ-C30 will be reported. Data for this outcome measure will be reported at the time of final results posting.
Time frame: Up to 25 months
Time to First Clinically Meaningful Deterioration in Symptoms and Functioning as Measured by EORTC QLQ-C30
Time to first clinically meaningful deterioration in symptoms and functioning as measured by EORTC QLQ-C30 will be reported. Data for this outcome measure will be reported at the time of final results posting.
Time frame: Up to 25 months
In total,184 participants were randomized to treatment but 3 participants (2 participants in Arm 1 and 1 participant in Arm 3, respectively) did not receive the study treatment.
| Milestone | Arm 1: BNT111 + Cemiplimab | Arm 2: BNT111 Monotherapy | Arm 3: Cemiplimab Monotherapy |
|---|---|---|---|
| Started | 94 | 46 | 44 |
| Treated | 92 | 46 | 43 |
| Completed | 0 | 0 | 0 |
| Not completed | 94 | 46 | 44 |
| Withdrew: Withdrawal by subject | 3 | 2 | 2 |
| Withdrew: Lost to follow-up | 3 | 3 | 1 |
| Withdrew: Investigator's decision | 1 | 0 | 0 |
| Withdrew: Death | 33 | 17 | 13 |
| Withdrew: Other | 1 | 0 | 0 |
| Withdrew: On-treatment | 19 | 10 | 12 |
| Withdrew: Survival follow-up | 34 | 14 | 16 |
ORR was defined as the percentage of participants in whom a complete response (CR) or partial response (PR) according to response evaluation criteria in solid tumors version 1.1 (RECIST v1.1) was observed as best overall response by blinded independent central review (BICR). Per RECIST 1.1 criteria, CR defined as the disappearance of all target lesions and PR was defined as the \>=30% decrease in the sum of the longest diameter of target lesions.
| percentage of participants | Arm 1: BNT111 + Cemiplimab |
|---|---|
| Arm 1: Objective Response Rate (ORR) | 18.0 (10.64 to 27.55) |
ORR is defined as the percentage of participants in whom a CR or PR according to RECIST v1.1 observed as best overall response by BICR. Data for this outcome measure will be reported at the time of final results posting.
Results for this outcome have not been posted.
DOR is defined as the time from first objective response (CR or PR) to first occurrence of objective tumor progression (progressive disease, PD) by BICR or death from any cause (whichever occurs first). Data for this outcome measure will be reported at the time of final results posting.
Results for this outcome have not been posted.
DCR is defined as the percentage of participants in whom a CR, PR or stable disease (SD; assessed at least 6 weeks after first dose) is observed as best overall response by BICR. Data for this outcome measure will be reported at the time of final results posting.
Results for this outcome have not been posted.
TTR is defined as the time from randomization to the first objective tumor response (CR or PR) by BICR. Data for this outcome measure will be reported at the time of final results posting.
Results for this outcome have not been posted.
PFS is defined as the time from randomization to first objective tumor progression (PD) by BICR or death from any cause (whichever occurs first). Data for this outcome measure will be reported at the time of final results posting.
Results for this outcome have not been posted.
ORR is defined as the percentage of participants in whom a CR or PR according to RECIST v1.1 observed as best overall response by investigator. Data for this outcome measure will be reported at the time of final results posting.
Results for this outcome have not been posted.
DOR is defined as the time from first objective response (CR or PR) to first occurrence of objective tumor progression (progressive disease, PD) by BICR or death from any cause (whichever occurs first). Data for this outcome measure will be reported at the time of final results posting.
Results for this outcome have not been posted.
DCR defined as the percentage of participants in whom a CR, PR or stable disease (SD; assessed at least 6 weeks after first dose) is observed as best overall response by investigator. Data for this outcome measure will be reported at the time of final results posting.
Results for this outcome have not been posted.
TTR is defined as the time from randomization to the first objective tumor response (CR or PR) as assessed by investigator. Data for this outcome measure will be reported at the time of final results posting.
Results for this outcome have not been posted.
PFS is defined as the time from randomization to first objective tumor progression (PD) by investigator or death from any cause (whichever occurs first). Data for this outcome measure will be reported at the time of final results posting.
Results for this outcome have not been posted.
OS is defined as the time from randomization to death from any cause. Data for this outcome measure will be reported at the time of final results posting.
Results for this outcome have not been posted.
A treatment-emergent adverse event (TEAE) is defined as any AE with an onset date on or after the first administration of trial treatment (if the AE was absent before the first administration of trial treatment) or worsened after the first administration of trial treatment (if the AE was present before the first administration of trial treatment). Data for this outcome measure will be reported at the time of final results posting.
Results for this outcome have not been posted.
AEs related to the use of immune checkpoint inhibitor (ICI) therapy are defined as immune-related (IR) AEs (irAEs). Data for this outcome measure will be reported at the time of final results posting.
Results for this outcome have not been posted.
Participants with dose reduction and discontinuation due to TEAE will be reported. Data for this outcome measure will be reported at the time of final results posting.
Results for this outcome have not been posted.
Blood samples will be collected for the assessment of hematology parameters. Data for this outcome measure will be reported at the time of final results posting.
Results for this outcome have not been posted.
Blood samples will be collected for the assessment of hematology parameters. Data for this outcome measure will be reported at the time of final results posting.
Results for this outcome have not been posted.
Blood samples will be collected for the assessment of hematology parameters. Data for this outcome measure will be reported at the time of final results posting.
Results for this outcome have not been posted.
Blood samples will be collected for the assessment of hematology parameters. Data for this outcome measure will be reported at the time of final results posting.
Results for this outcome have not been posted.
Blood samples will be collected for the assessment of hematology parameters. Data for this outcome measure will be reported at the time of final results posting.
Results for this outcome have not been posted.
Blood samples will be collected for the assessment of clinical chemistry parameters. Data for this outcome measure will be reported at the time of final results posting.
Results for this outcome have not been posted.
Blood samples will be collected for the assessment of clinical chemistry parameters. Data for this outcome measure will be reported at the time of final results posting.
Results for this outcome have not been posted.
Blood samples will be collected for the assessment of clinical chemistry parameters. Data for this outcome measure will be reported at the time of final results posting.
Results for this outcome have not been posted.
Blood samples will be collected for the assessment of clinical chemistry parameters. Data for this outcome measure will be reported at the time of final results posting.
Results for this outcome have not been posted.
Blood samples will be collected for the assessment of clinical chemistry parameters. Data for this outcome measure will be reported at the time of final results posting.
Results for this outcome have not been posted.
Blood samples will be collected for the assessment of clinical chemistry parameters. Data for this outcome measure will be reported at the time of final results posting.
Results for this outcome have not been posted.
Blood samples will be collected for the assessment of clinical chemistry parameters. Data for this outcome measure will be reported at the time of final results posting.
Results for this outcome have not been posted.
Blood samples will be collected for the assessment of clinical chemistry parameters. Data for this outcome measure will be reported at the time of final results posting.
Results for this outcome have not been posted.
Blood samples will be collected for the assessment of clinical chemistry parameters. Data for this outcome measure will be reported at the time of final results posting.
Results for this outcome have not been posted.
Blood samples will be collected for the assessment of coagulation factors. Data for this outcome measure will be reported at the time of final results posting.
Results for this outcome have not been posted.
Blood samples will be collected for the assessment of coagulation factors. Data for this outcome measure will be reported at the time of final results posting.
Results for this outcome have not been posted.
Blood samples will be collected for the assessment of endocrine tests. Data for this outcome measure will be reported at the time of final results posting.
Results for this outcome have not been posted.
Urine samples will be collected for the assessment of pH. Data for this outcome measure will be reported at the time of final results posting.
Results for this outcome have not been posted.
Participants with clinically significant abnormalities in laboratory parameters will be reported. Data for this outcome measure will be reported at the time of final results posting.
Results for this outcome have not been posted.
Systolic blood pressure (in mmHg) will be assessed. Data for this outcome measure will be reported at the time of final results posting.
Results for this outcome have not been posted.
Diastolic blood pressure (in mmHg) will be assessed. Data for this outcome measure will be reported at the time of final results posting.
Results for this outcome have not been posted.
Heart rate (in beats per minute) will be assessed. Data for this outcome measure will be reported at the time of final results posting.
Results for this outcome have not been posted.
Respiratory Rate (in breaths per minute) will be assessed. Data for this outcome measure will be reported at the time of final results posting.
Results for this outcome have not been posted.
Body Temperature (in degree Celsius) will be assessed. Data for this outcome measure will be reported at the time of final results posting.
Results for this outcome have not been posted.
Participants with clinically significant abnormalities in vital sign parameters will be reported. Data for this outcome measure will be reported at the time of final results posting.
Results for this outcome have not been posted.
Mean change from baseline in the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 Items (EORTC QLQ-C30) Global Health Status Score will be reported. Each item, except Global Health Status, is answered on a four-point scale (1-4): 1-not at all, 2-a little, 3-quite a bit, 4-very much. Response to Global Health Status is measured on a 1 to 7 scale. "1" being very poor and "7" being excellent. Positive changes indicated better health status or functioning, and negative changes indicated worsening of health status or functioning. Scale scores range from 0 to 100. Raw data was linearly transformed to be in a range from 0-100 where a higher score represents good health status, while lower scores indicate poor health status. Data for this outcome measure will be reported at the time of final results posting.
Results for this outcome have not been posted.
The EORTC QLQ-C30 questionnaire incorporates nine multi-item scales: 5 functional scales (physical, cognitive, role, emotional, and social); 3 symptom scales (pain, fatigue, and appetite loss) and a Global Health Status/QoL scale. EORTC QLQ-C30 Physical Functioning Score is a questionnaire to assess quality of life of cancer patients. It is composed of 30 items, multi-item measure (28 items) and 2 single-item measures. For the multiple item measure, 4-point scale is used and the score for each item range from "1 = not at all" to "4 = very much". Higher scores indicate worsening of symptoms. Data for this outcome measure will be reported at the time of final results posting.
Results for this outcome have not been posted.
The EORTC QLQ-C30 questionnaire incorporates nine multi-item scales: 5 functional scales (physical, cognitive, role, emotional, and social); 3 symptom scales (pain, fatigue, and appetite loss) and a Global Health Status/QoL scale. Each item, except Global Health Status, is answered on a four-point scale (1-4): 1-not at all, 2-a little, 3-quite a bit, 4-very much. Each scale (symptom scale \[pain, fatigue, and appetite loss\] and Global Health Status/Quality of Life \[QoL\] scale) was linearly transformed to be in range from 0-100 where a higher score represents good health status, while lower scores indicate poor health status. Data for this outcome measure will be reported at the time of final results posting.
Results for this outcome have not been posted.
Time to first clinically meaningful deterioration in global health status score as measured by EORTC QLQ-C30 will be reported. Data for this outcome measure will be reported at the time of final results posting.
Results for this outcome have not been posted.
Time to first clinically meaningful deterioration in symptoms and functioning as measured by EORTC QLQ-C30 will be reported. Data for this outcome measure will be reported at the time of final results posting.
Results for this outcome have not been posted.
Collected over From Baseline until last dose of study treatment (up to 25 months). As per protocol, non-serious adverse events (AEs) with an onset date more than 90 days after last administration of study treatment are only reported below if assessed as related to investigational medicinal product by investigator.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Arm 1: BNT111 + Cemiplimab | 33/94 (35.1%) | 30/92 (32.6%) | 89/92 (96.7%) |
| Arm 2: BNT111 Monotherapy | 6/46 (13%) | 8/46 (17.4%) | 43/46 (93.5%) |
| Arm 3: Cemiplimab Monotherapy | 6/44 (13.6%) | 11/43 (25.6%) | 33/43 (76.7%) |
| Add-on Treatment: BNT111 + Cemiplimab (add-on) | 11/25 (44%) | 6/25 (24%) | 22/25 (88%) |
| Add-on Treatment: Cemiplimab + BNT111 (add-on) | 7/22 (31.8%) | 7/22 (31.8%) | 22/22 (100%) |
| Event | Arm 1: BNT111 + Cemiplimab | Arm 2: BNT111 Monotherapy | Arm 3: Cemiplimab Monotherapy | Add-on Treatment: BNT111 + Cemiplimab (add-on) | Add-on Treatment: Cemiplimab + BNT111 (add-on) |
|---|---|---|---|---|---|
| Disease progressionGeneral disorders | 8/92 | 1/46 | 3/43 | 3/25 | 2/22 |
| AnaemiaBlood and lymphatic system disorders | 1/92 | 0/46 | 3/43 | 0/25 | 0/22 |
| Cytokine release syndromeImmune system disorders | 5/92 | 0/46 | 0/43 | 0/25 | 1/22 |
| Subcutaneous abscessInfections and infestations | 0/92 | 0/46 | 2/43 | 0/25 | 0/22 |
| General physical health deteriorationGeneral disorders | 0/92 | 0/46 | 0/43 | 0/25 | 1/22 |
| Abscess limbInfections and infestations | 0/92 | 0/46 | 1/43 | 0/25 | 1/22 |
| Pneumonia bacterialInfections and infestations | 0/92 | 0/46 | 0/43 | 0/25 | 1/22 |
| Infusion related reactionInjury, poisoning and procedural complications | 1/92 | 0/46 | 0/43 | 0/25 | 1/22 |
| ProstatomegalyReproductive system and breast disorders | 0/92 | 0/46 | 0/43 | 0/25 | 1/22 |
| HaemothoraxRespiratory, thoracic and mediastinal disorders | 0/92 | 0/46 | 0/43 | 0/25 | 1/22 |
| Event | Arm 1: BNT111 + Cemiplimab | Arm 2: BNT111 Monotherapy | Arm 3: Cemiplimab Monotherapy | Add-on Treatment: BNT111 + Cemiplimab (add-on) | Add-on Treatment: Cemiplimab + BNT111 (add-on) |
|---|---|---|---|---|---|
| PyrexiaGeneral disorders | 66/92 | 35/46 | 2/43 | 12/25 | 17/22 |
| ChillsGeneral disorders | 45/92 | 24/46 | 2/43 | 5/25 | 14/22 |
| NauseaGastrointestinal disorders | 34/92 | 11/46 | 6/43 | 3/25 | 5/22 |
| AstheniaGeneral disorders | 13/92 | 7/46 | 6/43 | 8/25 | 7/22 |
| HypotensionVascular disorders | 9/92 | 8/46 | 1/43 | 0/25 | 6/22 |
| VomitingGastrointestinal disorders | 23/92 | 6/46 | 5/43 | 3/25 | 4/22 |
| FatigueGeneral disorders | 22/92 | 7/46 | 2/43 | 5/25 | 2/22 |
| Influenza like illnessGeneral disorders | 20/92 | 10/46 | 0/43 | 2/25 | 1/22 |
| AnaemiaBlood and lymphatic system disorders | 11/92 | 4/46 | 5/43 | 2/25 | 4/22 |
| C-reactive protein increasedInvestigations | 1/92 | 1/46 | 6/43 | 2/25 | 4/22 |
Analysis was performed on intent to treat (ITT) set that included all participants who were randomized.
| Age, Continuous(years) | Arm 1: BNT111 + Cemiplimab | Arm 2: BNT111 Monotherapy | Arm 3: Cemiplimab Monotherapy | Total |
|---|---|---|---|---|
| Mean | 62.9 ± 13.54 | 63.1 ± 13.89 | 61.9 ± 15.78 | 62.7 ± 14.12 |
| Sex: Female, Male(Participants) | Arm 1: BNT111 + Cemiplimab | Arm 2: BNT111 Monotherapy | Arm 3: Cemiplimab Monotherapy | Total |
|---|---|---|---|---|
| Female | 34 | 17 | 19 | 70 |
| Male | 60 | 29 | 25 | 114 |
| Ethnicity (NIH/OMB)(Participants) | Arm 1: BNT111 + Cemiplimab | Arm 2: BNT111 Monotherapy | Arm 3: Cemiplimab Monotherapy | Total |
|---|---|---|---|---|
| Hispanic or Latino | 3 | 2 | 2 | 7 |
| Not Hispanic or Latino | 85 | 41 | 41 | 167 |
| Unknown or Not Reported | 6 | 3 | 1 | 10 |
| Race (NIH/OMB)(Participants) | Arm 1: BNT111 + Cemiplimab | Arm 2: BNT111 Monotherapy | Arm 3: Cemiplimab Monotherapy | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 00 | 0 |
| White | 89 | 44 | 44 | 177 |
| More than one race | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 5 | 2 | 0 | 7 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from May 2021 to primary completion in Jan 2024, 32 months.
Results were first posted in Dec 2025, 1 year 10 months after primary completion. A results delay was requested in Jan 2025.
Of 106 industry-sponsored phase 2 interventional studies under Melanoma, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 60. This study's 32 months is close to that.
Counting every sponsor, half of 384 studies reached it within 53 months; a quarter within 32 and three quarters within 90.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Cemiplimab